Prescription Drugs: Price Trends for Frequently Used Brand and Generic Drugs from 2000 through 2004: GAO-05-77

September 2005
GAO Reports;9/15/2005, p1
Government Documents
Prescription drug spending has been the fastest growing segment of national health expenditures. As the federal government assumes greater financial responsibility for prescription drug expenditures with the introduction of Medicare part D, federal policymakers are increasingly concerned about prescription drug prices. GAO was asked to examine the change in retail prices and other pricing benchmarks for drugs frequently used by Medicare beneficiaries and other individuals with health insurance from 2000 through 2004. To examine the change in retail prices from 2000 through 2004, we obtained usual and customary (U&C) prices from two state pharmacy assistance programs for drugs frequently used by Medicare beneficiaries and non-Medicare enrollees in the 2003 Blue Cross and Blue Shield (BCBS) Federal Employee Program (FEP). The U&C price is the price an individual without prescription drug coverage would pay at a retail pharmacy. Additionally, we compared the change in U&C prices for brand drugs from 2000 through 2004 to the change in two pricing benchmarks: average manufacturer price (AMP), which is the average of prices paid to manufacturers by wholesalers for drugs distributed to the retail pharmacy class of trade, and average wholesale price (AWP), which represents the average of list prices that a manufacturer suggests wholesalers charge pharmacies. We found the average U&C prices at retail pharmacies reported by two state pharmacy assistance programs for a 30-day supply of 96 drugs frequently used by BCBS FEP Medicare and non-Medicare enrollees increased 24.5 percent from January 2000 through December 2004. Of the 96 drugs: Twenty drugs accounted for nearly two-thirds of the increase in the U&C price index; the increase in average U&C prices for 75 prescription drugs frequently used by Medicare beneficiaries was similar to the increase for 76 prescription drugs frequently used by non-Medicare enrollees; and the average U&C prices for 50 frequently used brand prescription drugs increased three times as much as the average for 46 generic frequently used prescription drugs. AWPs increased at a faster rate than AMPs and U&C prices for the 50 frequently used brand drugs from first quarter 2000 through fourth quarter 2004. Ten drugs in each index accounted for almost 50 percent of the increase for AMP, AWP, and U&C prices. Eight of these 10 drugs were consistent across the three price indexes. The Centers for Medicare & Medicaid Services (CMS), two state pharmacy assistance programs, and BCBS FEP reviewed a draft of this report. While CMS noted that U&C and AWP do not reflect discounts in a drug's price, this report's focus was to examine price trends rather than price levels. Technical comments were incorporated as appropriate.


Related Articles

  • New Report Goes Beyond Medicare Cards to Analyze Drug Information Across Several Sources; Nonprofit Calls on Medicare to Delay Start of Drug-Discount Cards Until More Stable and...  // Ascribe Newswire: Medicine;5/21/2004, p77 

    A California nonprofit will release a report on Friday comparing price information for 20 drugs commonly prescribed to Medicare beneficiaries, revealing that consumers who are not eligible for a $600 credit may be better off using existing sources instead of a new Medicare drug-discount card....

  • Pharmacy to CMS: Medicaid rule is recipe for disaster. Paul, Reid // Drug Topics;1/22/2007, Vol. 151 Issue 2, p34 

    The article focuses on the proposed rule of the Centers for Medicare & Medicaid Services under the provisions of the Deficit Reduction Act of 2005 (DRA) concerning the five-year period Medicaid generic drug reimbursement. The DRA covers the modification of the formula for calculating federal...

  • Impact of an Annual Dollar Limit or "Cap" on Prescription Drug Benefits for Medicare Patients. Tseng, Chien-Wen; Brook, Robert; Keeler, Emmett; Mangione, Carol // JAMA: Journal of the American Medical Association;7/9/2003, Vol. 290 Issue 2, p222 

    Discusses the impact of an annual dollar limit or cap on prescription drug benefits for Medicare patients. Prescription benefit caps in the plan; Increase in the cost of prescription drugs since the enactment of Medicare; Lack of generic drug options; Out-of-pocket prescription costs.

  • Drug-price escalation is likely to slow. Toth, David // Fairfield County Business Journal;4/25/2005, Vol. 44 Issue 17, p25 

    The article reports that the Center for Medicare and Medicaid Services (CMS) has stated in a study that although prescription drug spending is at an all-time high, the growth may be slowing and that trend is likely to continue. The high cost of using a brand name medication when a generic brand...

  • Medicare, Medicaid spur generics prospects. Frederick, James // Drug Store News;9/25/2006, Vol. 28 Issue 12, p40 

    The article reports on the projected increase in sales of generic drugs triggered by the two biggest health care purchasers in the U.S. in 2007. To contain soaring costs of health care expenses, health care agencies are resorting to generic drugs to increase state savings by instituting...

  • GOVERNMENT DRUG POLICIES IN CANADA OFFER NO COST ADVANTAGE OVER US DRUG POLICIES.  // Canadian Journal of Dental Hygiene;Jan/Feb2008, Vol. 42 Issue 1, p39 

    The article reports on the results of a study entitled "The Cost Burden of Prescription Drug Spending in Canada and the U.S." The research found that Canadians spend roughly the same percentage of their incomes on prescription drugs as U.S. consumers. B. Skinner, director of Health...

  • Canadian price controls destroying market competition.  // PharmacoEconomics & Outcomes News;3/12/2005, Issue 473, p10 

    Reports on the impact of pharmaceutical price controls imposed by Canadian authorities on market competition. Effect of the pharmaceutical policy on healthcare spending in the country; Criticism against high prices of generic drugs in Canada compared with the U.S.; Average amount spent by...

  • Where Would We Be With No Generics? Coopman, Robert // Chain Drug Review;2/22/2016, Vol. 38 Issue 4, p67 

    The article reports on the increase in brand medication spending and the decline in costs for generic medications in the U.S. for 2015.

  • Medicare Prescription Drug Discount Card Program Could Save All Seniors Without Drug Coverage a Total of $1 Billion.  // Ascribe Newswire: Medicine;4/16/2004, p55 

    Medicare's prescription drug discount card program could save seniors without any other drug coverage an average of 17.4 percent in out-of-pocket costs, according to an article published today on the journal "Health Affairs" Web site. Juliette Cubanski, a Harvard University health policy...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics